Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nelipepimut-s + sargramostim
- Development stage
- Unknown
- Lead developer
- Galena Biopharma
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intradermal
01
Overview
Nelipepimut-S + sargramostim is a cancer vaccine consisting of the HER2-derived MHC class I peptide E75 (nelipepimut-S) combined with granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim). The vaccine is designed to stimulate a specific cytotoxic T-lymphocyte response against HER2/neu-expressing tumor cells, particularly in breast cancer. Nelipepimut-S is an immunogenic peptide from the HER2 protein that is highly expressed in breast cancer, while sargramostim serves as an immune adjuvant to enhance the immune response.
- Brand names
- NeuVax
- Other names
- Nelipepimut-S plus GM-CSF vaccineE75 peptide vaccineE-75 peptide vaccineE 75 peptide vaccine
02
Targets
HLA-A*02 (Human leukocyte antigen A*02 complexed peptide)CSF2R (Granulocyte-macrophage colony-stimulating factor receptor)HLA-A*03:01 (DARKFOX-A3 peptide-HLA-A*03:01 complex)
Beyond the preview
Go deeper on nelipepimut-s + sargramostim.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nelipepimut-s + sargramostim.